MET and esophageal adenocarcinoma: In a single-arm Phase II trial using the selective small molecule MET inhibitor AMG337, antitumor activity was observed in 18% of adults with MET-amplified gastric, gastroesophageal junction, and esophageal adenocarcinomas; however, significant adverse side effects were also observed [54].